126 related articles for article (PubMed ID: 25876880)
1. Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™.
Barrett-Connor E; Wade SW; Downs RW; Ganiats T; Hochberg M; Recker RR; Stolshek BS
Osteoporos Int; 2015 Aug; 26(8):2175-84. PubMed ID: 25876880
[TBL] [Abstract][Full Text] [Related]
2. Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy.
Wade SW; Satram-Hoang S; Nadkar A; Macarios D; Tosteson AN
Clin Ther; 2011 Dec; 33(12):2006-15. PubMed ID: 22099387
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.
Wade SW; Satram-Hoang S; Stolshek BS
Osteoporos Int; 2014 Sep; 25(9):2279-90. PubMed ID: 24942502
[TBL] [Abstract][Full Text] [Related]
4. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.
Barrett-Connor E; Wade SW; Do TP; Satram-Hoang S; Stewart R; Gao G; Macarios D
Osteoporos Int; 2012 Feb; 23(2):733-41. PubMed ID: 21625886
[TBL] [Abstract][Full Text] [Related]
5. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study.
Lukert B; Satram-Hoang S; Wade S; Anthony M; Gao G; Downs R
Drugs Aging; 2011 Sep; 28(9):713-27. PubMed ID: 21913737
[TBL] [Abstract][Full Text] [Related]
6. Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications.
Barrett-Connor E; Ensrud K; Tosteson AN; Varon SF; Anthony M; Daizadeh N; Wade S
Osteoporos Int; 2009 Mar; 20(3):463-72. PubMed ID: 18607669
[TBL] [Abstract][Full Text] [Related]
7. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
8. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
[TBL] [Abstract][Full Text] [Related]
9. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
Jacob L; Dreher M; Kostev K; Hadji P
Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
[TBL] [Abstract][Full Text] [Related]
10. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US.
Tosteson AN; Do TP; Wade SW; Anthony MS; Downs RW
Osteoporos Int; 2010 Oct; 21(10):1769-80. PubMed ID: 20101492
[TBL] [Abstract][Full Text] [Related]
11. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
12. Medication persistence in older women with osteoporosis: a pilot study.
Gillette C; Howerton DM; Williams BD; Mahmood MA
Osteoporos Int; 2015 Dec; 26(12):2883-8. PubMed ID: 26194492
[TBL] [Abstract][Full Text] [Related]
13. Determinants of adherence to osteoporosis treatment in clinical practice.
Rossini M; Bianchi G; Di Munno O; Giannini S; Minisola S; Sinigaglia L; Adami S;
Osteoporos Int; 2006; 17(6):914-21. PubMed ID: 16538553
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence with anti-osteoporosis drugs after fracture.
Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
[TBL] [Abstract][Full Text] [Related]
15. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis.
Torre C; Guerreiro J; Mendes Z; Miranda A; Bragança F; Cristino J; Canhão H; Branco JC
Acta Reumatol Port; 2019; 44(2):114-125. PubMed ID: 31280276
[TBL] [Abstract][Full Text] [Related]
16. Compliance with osteoporosis treatment guidelines in postmenopausal women.
Mountjoy CR; Shrader SP; Ragucci KR
Ann Pharmacother; 2009 Feb; 43(2):242-50. PubMed ID: 19196838
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study.
Woo C; Gao G; Wade S; Hochberg MC
Curr Med Res Opin; 2010 Apr; 26(4):1003-9. PubMed ID: 20201623
[TBL] [Abstract][Full Text] [Related]
18. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database.
Li L; Roddam A; Ferguson S; Feudjo-Tepie M; Taylor A; Jick S
Menopause; 2014 Oct; 21(10):1106-13. PubMed ID: 24569621
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of therapeutic compliance in women with osteoporosis].
Carbonell Abella C; Guañabens Gay N; Regadera Anechina L; Marín Rives JA; Taverna Llauradó E; Ayechu Redín MP;
Reumatol Clin; 2011; 7(5):299-304. PubMed ID: 21925445
[TBL] [Abstract][Full Text] [Related]
20. Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Bošković L; Gašparić M; Petković M; Gugić D; Lovasić IB; Soldić Ž; Miše BP; Dabelić N; Vazdar L; Vrdoljak E
Breast; 2017 Feb; 31():16-19. PubMed ID: 27810693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
